Question 1

Purpose of the Procedure

Accepted Answer

Determining patient eligibility for immunotherapy drugs. Predicting tumor response to immune checkpoint inhibitors. Optimizing the treatment plan to avoid ineffective therapies.

Question 2

Target Groups

Accepted Answer

Patients with Non-Small Cell Lung Cancer (NSCLC). Individuals with urothelial or renal cell carcinoma. Patients with advanced malignancies exploring immunotherapy options.

Question 3

Understanding the Results

Accepted Answer

Positive Result: High protein expression suggests a better response to immunotherapy. Negative Result: Lower expression may indicate the need for alternative treatments. Scores like TPS or CPS help oncologists decide the specific drug dosage.

Check Your Immunotherapy Eligibility - PD-L1 Expression Testing (IHC)